Department of Dermatology, Oregon Health & Science University, Portland2now with the Department of Dermatology, University of Texas Medical Branch, Galveston.
JAMA Dermatol. 2013 Oct;149(10):1167-71. doi: 10.1001/jamadermatol.2013.4909.
The rise of methicillin-resistant Staphylococcus aureus (MRSA) infections in the outpatient setting has led to a growing trend of empirical antibiotic treatment for MRSA. The limited oral antibiotics available and the growing resistance to these antibiotics make this a controversial practice.
To determine the frequency of patients with MRSA skin and soft-tissue infections (SSTIs) reverting to methicillin-susceptible Staphylococcus aureus (MSSA) positivity.
Retrospective medical record review of inpatients and outpatients from our university hospital and clinics between January 1, 2000, and December 31, 2010.
Patients in our institutional microbiological database were included if they had a MRSA-positive SSTI and subsequent culture-proven S aureus SSTI more than 1 month later. No sociodemographic restrictions were applied. A sample of at least 200 patients meeting the above criteria was desired. The database was sorted by ascending medical record number, with the first 1681 patients' medical records reviewed. Of these, 215 patients met our criteria.
Whether a patient remained MRSA positive in subsequent SSTIs or reverted to MSSA-positive infections.
Of the total 215 patients, 64 (29.8%) had at least 1 incident of MSSA reversion, and 55 (25.6%) reverted to MSSA infections for the remainder of the study. We assessed various factors that might increase or decrease the likelihood of reversion. The presence of an invasive device was the only factor to demonstrate a statistically significant risk (relative risk, 1.20; 95% CI, 1.02-1.41; P = .03) toward remaining MRSA positive in subsequent infections.
Patients with MRSA SSTIs demonstrated the ability to revert to subsequent MSSA SSTIs with a significant frequency. Further study regarding MRSA risk factors and their effects on subsequent infections would be valuable in guiding empirical treatment. Reculturing new infections in previously MRSA-positive patients is a prudent management strategy as we recognize that susceptibilities of the S aureus organisms change.
耐甲氧西林金黄色葡萄球菌(MRSA)感染在门诊环境中的上升导致了针对 MRSA 的经验性抗生素治疗的日益增多。现有的有限的口服抗生素和对这些抗生素的耐药性不断增加,使得这种做法存在争议。
确定患有 MRSA 皮肤和软组织感染(SSTI)的患者恢复为甲氧西林敏感金黄色葡萄球菌(MSSA)阳性的频率。
对我们大学医院和诊所 2000 年 1 月 1 日至 2010 年 12 月 31 日期间的住院患者和门诊患者的病历进行回顾性医学记录审查。
如果患者的 MRSA 阳性 SSTI 后 1 个月以上的培养证实金黄色葡萄球菌 SSTI ,则将他们纳入我们机构微生物数据库中。没有应用社会人口统计学限制。希望至少有 200 名符合上述标准的患者入组。数据库按病历号升序排序,首先审查前 1681 名患者的病历。其中,215 名患者符合我们的标准。
患者在随后的 SSTI 中是否仍为 MRSA 阳性或恢复为 MSSA 阳性感染。
在总共 215 名患者中,64 名(29.8%)至少有 1 次 MSSA 恢复,55 名(25.6%)在研究的其余时间内恢复为 MSSA 感染。我们评估了可能增加或降低恢复可能性的各种因素。有创器械的存在是唯一表明在随后的感染中仍为 MRSA 阳性的风险增加的因素(相对风险,1.20;95%CI,1.02-1.41;P =.03)。
患有 MRSA SSTI 的患者具有随后恢复为 MSSA SSTI 的显著频率。关于 MRSA 危险因素及其对随后感染的影响的进一步研究将有助于指导经验性治疗。在我们认识到金黄色葡萄球菌生物体的敏感性发生变化的情况下,对以前为 MRSA 阳性的患者的新感染进行再培养是一种谨慎的管理策略。